Redburn Atlantic Upgrades Autolus Therapeutics (NASDAQ:AUTL) to “Buy”

Autolus Therapeutics (NASDAQ:AUTL) was upgraded by research analysts at Redburn Atlantic from a “neutral” rating to a “buy” rating in a report released on Friday, MarketBeat reports. The firm presently has a $13.00 price objective on the stock. Redburn Atlantic’s target price would indicate a potential upside of 322.08% from the stock’s previous close.

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a report on Monday, November 11th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $9.45.

Autolus Therapeutics Price Performance

Autolus Therapeutics stock opened at $3.08 on Friday. The firm has a market cap of $819.56 million, a PE ratio of -2.55 and a beta of 2.04. The stock’s fifty day moving average price is $3.91 and its two-hundred day moving average price is $3.99. Autolus Therapeutics has a one year low of $2.94 and a one year high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same quarter last year, the business earned ($0.26) earnings per share. Sell-side analysts expect that Autolus Therapeutics will post -0.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AUTL. Exchange Traded Concepts LLC boosted its stake in shares of Autolus Therapeutics by 9.8% in the 3rd quarter. Exchange Traded Concepts LLC now owns 41,866 shares of the company’s stock valued at $152,000 after purchasing an additional 3,740 shares in the last quarter. Wealth Effects LLC grew its stake in shares of Autolus Therapeutics by 19.5% during the second quarter. Wealth Effects LLC now owns 49,000 shares of the company’s stock worth $171,000 after buying an additional 8,000 shares during the last quarter. Bellevue Group AG increased its holdings in shares of Autolus Therapeutics by 27.7% during the third quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock worth $151,000 after buying an additional 9,000 shares in the last quarter. State Street Corp lifted its stake in shares of Autolus Therapeutics by 1.7% in the 3rd quarter. State Street Corp now owns 606,544 shares of the company’s stock valued at $2,202,000 after acquiring an additional 10,401 shares during the last quarter. Finally, EntryPoint Capital LLC boosted its holdings in shares of Autolus Therapeutics by 113.6% during the 1st quarter. EntryPoint Capital LLC now owns 21,540 shares of the company’s stock valued at $137,000 after acquiring an additional 11,456 shares in the last quarter. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.